Drugs / Cinobufacin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01236690 | Nov 2010 → Oct 2013 | hepatocellular carcinoma | Changhai Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cinobufacin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01236690 ↗ |
| Known as | Cinobufacini | “Cinobufacini has the effects of anticancer, improving the liver function, elevation of immunity and little side effects, and is important and significant for the patients with...” NCT01236690 ↗ |
| Route | Other | “Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy” NCT01236690 ↗ |